228 related articles for article (PubMed ID: 29174881)
1. Reprint of "Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab".
Cludts I; Spinelli FR; Morello F; Hockley J; Valesini G; Wadhwa M
Cytokine; 2018 Jan; 101():70-77. PubMed ID: 29174881
[TBL] [Abstract][Full Text] [Related]
2. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab.
Cludts I; Spinelli FR; Morello F; Hockley J; Valesini G; Wadhwa M
Cytokine; 2017 Aug; 96():16-23. PubMed ID: 28279855
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Poddubnyy D; Rudwaleit M
Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
[TBL] [Abstract][Full Text] [Related]
4. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.
van Schouwenburg PA; Bartelds GM; Hart MH; Aarden L; Wolbink GJ; Wouters D
J Immunol Methods; 2010 Oct; 362(1-2):82-8. PubMed ID: 20833178
[TBL] [Abstract][Full Text] [Related]
5. Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect Evaluation.
Kraev K; Geneva-Popova M; Popova V; Popova S; Maneva A; Batalov A; Stankova T; Delcheva G; Stefanova K
Folia Med (Plovdiv); 2020 Jun; 62(2):282-289. PubMed ID: 32666748
[TBL] [Abstract][Full Text] [Related]
6. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
van Schouwenburg PA; van de Stadt LA; de Jong RN; van Buren EE; Kruithof S; de Groot E; Hart M; van Ham SM; Rispens T; Aarden L; Wolbink GJ; Wouters D
Ann Rheum Dis; 2013 Jan; 72(1):104-9. PubMed ID: 22759910
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
[TBL] [Abstract][Full Text] [Related]
11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
12. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
13. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
14. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
15. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
18. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
20. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
